Great Novel Therapeutics Biotech & Medicals (ROCO:7427) Long-Term Capital Lease Obligation : NT$10.88 Mil (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Great Novel Therapeutics Biotech & Medicals Long-Term Capital Lease Obligation?

Great Novel Therapeutics Biotech & Medicals's Long-Term Capital Lease Obligation for the quarter that ended in Dec. 2023 was NT$10.88 Mil.

Great Novel Therapeutics Biotech & Medicals's quarterly Long-Term Capital Lease Obligation increased from Dec. 2022 (NT$0.00 Mil) to Jun. 2023 (NT$12.24 Mil) but then declined from Jun. 2023 (NT$12.24 Mil) to Dec. 2023 (NT$10.88 Mil).

Great Novel Therapeutics Biotech & Medicals's annual Long-Term Capital Lease Obligation stayed the same from Dec. 2021 (NT$0.00 Mil) to Dec. 2022 (NT$0.00 Mil) but then increased from Dec. 2022 (NT$0.00 Mil) to Dec. 2023 (NT$10.88 Mil).

Great Novel Therapeutics Biotech & Medicals Long-Term Capital Lease Obligation Historical Data

The historical data trend for Great Novel Therapeutics Biotech & Medicals's Long-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Great Novel Therapeutics Biotech & Medicals Long-Term Capital Lease Obligation Chart

Great Novel Therapeutics Biotech & Medicals Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Long-Term Capital Lease Obligation

Get a 7-Day Free Trial

10.88

Great Novel Therapeutics Biotech & Medicals Semi-Annual Data
	Dec18	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Long-Term Capital Lease Obligation	Get a 7-Day Free Trial					-	-	-	12.24	10.88

Great Novel Therapeutics Biotech & Medicals (ROCO:7427) Long-Term Capital Lease Obligation Explanation

Long-Term Capital Lease Obligation are the amount due for long-term asset lease agreements that are nearly equivalent to asset purchases. Capital lease obligations are installment payments that constitute a payment of principal plus interest for the capital lease. The Short-Term Capital Lease Obligation is the portion of a Long-Term Capital Lease Obligation that is due over the next year.

Under US Generally Accepted Accounting Principles (GAAP), a capital lease is essentially equivalent to a purchase by the lessee if it meets the following criteria:

1. Ownership of the asset is transferred to the lessee at the end of the lease term;
2. The lease contains a bargain purchase option to buy the equipment at less than fair market value;
3. The lease term equals or exceeds 75% of the asset's estimated useful life;
4. The present value of the lease payments equals or exceeds 90% of the total original cost of the equipment.

Great Novel Therapeutics Biotech & Medicals Long-Term Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Great Novel Therapeutics Biotech & Medicals's Long-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

Great Novel Therapeutics Biotech & Medicals (ROCO:7427) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Great Novel Therapeutics Biotech & Medicals (ROCO:7427) » Definitions » Long-Term Capital Lease Obligation

Comparable Companies

Traded in Other Exchanges

N/A

Address

No.3, Park Street, Room WR-06, 17th Floor, Nangang District, Taipei, TWN, 11503

Website

http://www.gntbm.com.tw

Great Novel Therapeutics Biotech & Medicals focuses on drug development to treat advanced cancer. The new drugs ranging from epigenetic modulators, a combination of tumor microenvironment-regulating agents, epigenetic immuno-modulators, to the protein degradation drugs targeting HDACs 1, 2, and 3, are in a developing pipeline. These drugs focus on the field of epigenetics, for the demand of clinical unmet needs in advanced and refractory cancers.

Great Novel Therapeutics Biotech & Medicals (ROCO:7427) Headlines

No Headlines